ADC Therapeutics SA Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 63.41K shares.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 123.97K shares.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 116.05K shares, a 335.48% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 127.65K shares, a 128.62% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 262.26K shares, a 129.11% increase from fiscal 2024.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 114.47K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 63.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 431.08K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 123.97K shares 10-Q · filed 2026-05-04 | |
| 2025-12-31 | 116.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 262.26K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 127.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-12-31 | 26.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 114.47K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 55.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2024-06-30 | 25.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | |
| 2024-03-31 | 6.38K shares 10-Q · filed 2024-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |